Lion Street Advisors’s Corcept Therapeutics CORT Stock Holding History

Lion Street Advisors’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$239K	Buy	+13,300	New	+$962K	0.08%	188
2023 Q3	–	Sell	-13,400	Closed	-$241K	–	260
2023 Q2	$241K	Buy	+13,400	New	+$308K	0.08%	199
2023 Q1	–	Sell	-11,750	Closed	-$212K	–	245
2022 Q4	$212K	Buy	+11,750	New	+$295K	0.11%	147
2022 Q3	–	Sell	-11,750	Closed	-$216K	–	136
2022 Q2	$216K	Buy	+11,750	New	+$256K	0.11%	144
2021 Q4	–	Sell	-11,750	Closed	-$234K	–	156
2021 Q3	$234K	Buy	+11,750	New	+$246K	0.13%	132

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Lion Street Advisors's CORT Position: Q3 2025 in Review

Lion Street Advisors opened a new position in Corcept Therapeutics (CORT) in Q3 2025: 13,300 shares worth $239K. The stake represents 0.08% of the portfolio and ranks #188 among its holdings. This is a return to the name: Lion Street Advisors previously reported a position in CORT as recently as Q2 2023.

Lion Street Advisors first reported a position in CORT in Q3 2021 and has held it in 5 quarters since. The position peaked at $241K in Q2 2023. 429 funds tracked by Wall St. Rank hold CORT as of Q3 2025.

Lion Street Advisors held 13,300 shares of Corcept Therapeutics worth $239K as of Q3 2025.
Corcept Therapeutics was a new Lion Street Advisors position in Q3 2025.
Corcept Therapeutics made up 0.08% of Lion Street Advisors's portfolio in Q3 2025, its #188 holding.
Lion Street Advisors first reported a position in Corcept Therapeutics in Q3 2021 and has held it in 5 quarters since.
Lion Street Advisors's Corcept Therapeutics position peaked at $241K in Q2 2023.
429 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2025.

Based on Lion Street Advisors's 13F filing for Q3 2025, filed 10 Nov 2025.